By Michele Maatouk
Date: Friday 09 Aug 2024
(Sharecast News) - Merck said on Friday that it has agreed to buy biotech firm Curon's CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, for up to $1.3bn.
Under the terms of the deal, Merck will buy full global rights to CN201 for an upfront...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news